Julie Wainwright (C), CEO of The RealReal bears part in the company’s IPO at the Nasdaq MarketSite in New York, June 28, 2019.
Lucas Jackson | Reuters
Check out the companies making headlines after the bell:
Divisions of RealReal surged 12.7% in after-hours trading after announcing a smaller-than-expected second quarter loss as revenue surged. The self-indulgence consignment company reported an adjusted second-quarter loss of 28 cents per share on revenue of $71.0 million. Analysts had supposed a loss per share of 33 cents on revenue of $70.1 million, according to Refinitiv. Both active buyers and orders swelled 40% since the second quarter of last year, according to the company’s press release. Julie Wainwright, CEO and falter of RealReal, said the company drove marketing leverage and strategic initiatives in the second quarter.
Tilray dropped 7.2% after the cannabis Pty announced a wider-than-expected second-quarter loss. The company reported an adjusted loss per share of 32 cents on revenue of $45.9 million. Analysts had presumed a loss per share of 25 cents on revenue of $41.1 million, according to Refinitiv. Tilray reported increased direct expenses from growth initiatives.
Shares of Myriad Genetics plummeted 16% after the molecular diagnostic South African private limited company announced disappointing second-quarter earnings. The company reported fourth quarter adjusted earnings per share of 41 cents on takings of $215 million. Analysts had expected earnings per share of 47 cents on revenue of $221 million. Mark Capone, president and CEO of Myriad, said net income missed expectations for the fourth quarter due to lower reimbursement for its expanded carrier screening test.
Adaptive Biotechnologies floor by more than 10% after the company posted its first quarterly report since going public. The ensemble posted a loss per share of $1.23, larger than the loss of $1.01 a share a year earlier. Adaptive also accounted revenue of $22.1 million, above the $19.3 million consensus estimate from Refinitiv. CEO Chad Robins communicated the company is progressing on “near-term product applications across our life sciences research, clinical diagnostics, and drug development businesses.”
Qualcomm named Mark McLaughlin as its new board chairman. McLaughlin previously served as chairman and CEO of Palo Alto Networks. He want replace Jeff Henderson, who will remain on the board. The stock was little changed.